Gilead Sciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | $30.80B | $20.44B | $7.59B |
| FY2018 | $24.57B | $21.39B | $17.94B |
| FY2019 | $22.09B | $22.53B | $11.63B |
| FY2020 | $28.65B | $18.20B | $6.00B |
| FY2021 | $25.18B | $21.07B | $5.34B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | $30.80B | $20.44B | $7.59B |
| FY2018 | $24.57B | $21.39B | $17.94B |
| FY2019 | $22.09B | $22.53B | $11.63B |
| FY2020 | $28.65B | $18.20B | $6.00B |
| FY2021 | $25.18B | $21.07B | $5.34B |